Mediterranean Kaposi's sarcoma in the elderly: A randomized study of oral etoposide versus vinblastine

L. Brambilla, R. Labianca, V. Boneschi, S. Fossati, G. Dallavalle, A. F. Finzi, G. Luporini

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background. This Phase III trial was performed to compare the roles of oral etoposide and intravenous (i.v.) vinblastine in the treatment of Mediterranean Kaposi's Sarcoma (MEKS) in elderly patients with severe disease (Stages II, Ac/B, III, and IV). Patients and Methods. Sixty-five patients were randomized to receive either oral etoposide (60 mg/m2 on Days 1-3 during the first course; 60 mg/m2 on Days 1-4 during the second course, and 60 mg/m2 on Days 1-5 during the third course; the courses were recycled every 3 weeks) or an i.v. bolus of vinblastine (3 mg/m2 weekly for 3 weeks, and then 6 mg/m2 every 3 weeks). Results. No significant difference between the two drugs was observed in terms of response rates (etoposide, 73.5% vs. vinblastine, 58%; P = 0.3), duration of response, or survival (median not yet reached at a median follow-up of 38 months). Side effects of both treatments were limited, although myelotoxicity was more evident in the vinblastine arm. Conclusions. Although it is feasible and well tolerated, the oral administration of etoposide at these doses and in this regimen does not appear superior to vinblastine in the treatment of MEKS. Further evaluation of a more intensive schedule in large cooperative clinical trials is needed to establish the role of this drug in comparison with reference treatments.

Original languageEnglish
Pages (from-to)2873-2878
Number of pages6
JournalCancer
Volume74
Issue number10
DOIs
Publication statusPublished - 1994

Fingerprint

Vinblastine
Kaposi's Sarcoma
Etoposide
Therapeutics
Pharmaceutical Preparations
Oral Administration
Appointments and Schedules
Clinical Trials
Survival

Keywords

  • elderly
  • Kaposi's sarcoma
  • oral etoposide
  • randomized study
  • vinblastine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mediterranean Kaposi's sarcoma in the elderly : A randomized study of oral etoposide versus vinblastine. / Brambilla, L.; Labianca, R.; Boneschi, V.; Fossati, S.; Dallavalle, G.; Finzi, A. F.; Luporini, G.

In: Cancer, Vol. 74, No. 10, 1994, p. 2873-2878.

Research output: Contribution to journalArticle

Brambilla, L. ; Labianca, R. ; Boneschi, V. ; Fossati, S. ; Dallavalle, G. ; Finzi, A. F. ; Luporini, G. / Mediterranean Kaposi's sarcoma in the elderly : A randomized study of oral etoposide versus vinblastine. In: Cancer. 1994 ; Vol. 74, No. 10. pp. 2873-2878.
@article{cd018141bfcc4a83a3394bbc23e23cff,
title = "Mediterranean Kaposi's sarcoma in the elderly: A randomized study of oral etoposide versus vinblastine",
abstract = "Background. This Phase III trial was performed to compare the roles of oral etoposide and intravenous (i.v.) vinblastine in the treatment of Mediterranean Kaposi's Sarcoma (MEKS) in elderly patients with severe disease (Stages II, Ac/B, III, and IV). Patients and Methods. Sixty-five patients were randomized to receive either oral etoposide (60 mg/m2 on Days 1-3 during the first course; 60 mg/m2 on Days 1-4 during the second course, and 60 mg/m2 on Days 1-5 during the third course; the courses were recycled every 3 weeks) or an i.v. bolus of vinblastine (3 mg/m2 weekly for 3 weeks, and then 6 mg/m2 every 3 weeks). Results. No significant difference between the two drugs was observed in terms of response rates (etoposide, 73.5{\%} vs. vinblastine, 58{\%}; P = 0.3), duration of response, or survival (median not yet reached at a median follow-up of 38 months). Side effects of both treatments were limited, although myelotoxicity was more evident in the vinblastine arm. Conclusions. Although it is feasible and well tolerated, the oral administration of etoposide at these doses and in this regimen does not appear superior to vinblastine in the treatment of MEKS. Further evaluation of a more intensive schedule in large cooperative clinical trials is needed to establish the role of this drug in comparison with reference treatments.",
keywords = "elderly, Kaposi's sarcoma, oral etoposide, randomized study, vinblastine",
author = "L. Brambilla and R. Labianca and V. Boneschi and S. Fossati and G. Dallavalle and Finzi, {A. F.} and G. Luporini",
year = "1994",
doi = "10.1002/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1",
language = "English",
volume = "74",
pages = "2873--2878",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Mediterranean Kaposi's sarcoma in the elderly

T2 - A randomized study of oral etoposide versus vinblastine

AU - Brambilla, L.

AU - Labianca, R.

AU - Boneschi, V.

AU - Fossati, S.

AU - Dallavalle, G.

AU - Finzi, A. F.

AU - Luporini, G.

PY - 1994

Y1 - 1994

N2 - Background. This Phase III trial was performed to compare the roles of oral etoposide and intravenous (i.v.) vinblastine in the treatment of Mediterranean Kaposi's Sarcoma (MEKS) in elderly patients with severe disease (Stages II, Ac/B, III, and IV). Patients and Methods. Sixty-five patients were randomized to receive either oral etoposide (60 mg/m2 on Days 1-3 during the first course; 60 mg/m2 on Days 1-4 during the second course, and 60 mg/m2 on Days 1-5 during the third course; the courses were recycled every 3 weeks) or an i.v. bolus of vinblastine (3 mg/m2 weekly for 3 weeks, and then 6 mg/m2 every 3 weeks). Results. No significant difference between the two drugs was observed in terms of response rates (etoposide, 73.5% vs. vinblastine, 58%; P = 0.3), duration of response, or survival (median not yet reached at a median follow-up of 38 months). Side effects of both treatments were limited, although myelotoxicity was more evident in the vinblastine arm. Conclusions. Although it is feasible and well tolerated, the oral administration of etoposide at these doses and in this regimen does not appear superior to vinblastine in the treatment of MEKS. Further evaluation of a more intensive schedule in large cooperative clinical trials is needed to establish the role of this drug in comparison with reference treatments.

AB - Background. This Phase III trial was performed to compare the roles of oral etoposide and intravenous (i.v.) vinblastine in the treatment of Mediterranean Kaposi's Sarcoma (MEKS) in elderly patients with severe disease (Stages II, Ac/B, III, and IV). Patients and Methods. Sixty-five patients were randomized to receive either oral etoposide (60 mg/m2 on Days 1-3 during the first course; 60 mg/m2 on Days 1-4 during the second course, and 60 mg/m2 on Days 1-5 during the third course; the courses were recycled every 3 weeks) or an i.v. bolus of vinblastine (3 mg/m2 weekly for 3 weeks, and then 6 mg/m2 every 3 weeks). Results. No significant difference between the two drugs was observed in terms of response rates (etoposide, 73.5% vs. vinblastine, 58%; P = 0.3), duration of response, or survival (median not yet reached at a median follow-up of 38 months). Side effects of both treatments were limited, although myelotoxicity was more evident in the vinblastine arm. Conclusions. Although it is feasible and well tolerated, the oral administration of etoposide at these doses and in this regimen does not appear superior to vinblastine in the treatment of MEKS. Further evaluation of a more intensive schedule in large cooperative clinical trials is needed to establish the role of this drug in comparison with reference treatments.

KW - elderly

KW - Kaposi's sarcoma

KW - oral etoposide

KW - randomized study

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0028100112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028100112&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1

DO - 10.1002/1097-0142(19941115)74:10<2873::AID-CNCR2820741021>3.0.CO;2-1

M3 - Article

C2 - 7954250

AN - SCOPUS:0028100112

VL - 74

SP - 2873

EP - 2878

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -